1. DOP74 Efficacy of ustekinumab in perianal Crohn's disease: the BioLAP multi-centre observational study. (25th January 2019) Authors: Biron, C; Seksik, P; Nachury, M; Bouhnik, Y; Amiot, A; Viennot, S; Serrero, M; Fumery, M; Allez, M; Siproudhis, L; Buisson, A; Pineton de Chambrun, G; Abitbol, V; Nancey, S; Caillo, L; Plastaras, L; Armengol-Debeir, L; Chanteloup, E; Simon, M; Dib, N Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S074 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P347 Vedolizumab for primary sclerosing cholangitis associated with inflammatory bowel disease: A multicentre cohort study from the GETAID. (16th January 2018) Authors: Caron, B; Peyrin-Biroulet, L; Nachury, M; Bouhnik, Y; Seksik, P; Bouguen, G; Caillo, L; Laharie, D; Carbonnel, F; Altwegg, R; Reenaers, C; Serrero, M; Boureille, A; Nancey, S; Filippi, J; Abitbol, V; Savoye, G; Vuitton, L; Viennot, S; Fumery, M Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S278 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P593 Efficacy, tolerance and safety of low-volume bowel preparations in inflammatory bowel diseases: Results from a French national multicentre study. (16th January 2018) Authors: Briot, C; Faure, P; Parmentier, A L; Gay, C; Trang, C; Nachury, M; Viennot, S; Altwegg, R; Bulois, P; Thomassin, L; Serrero, M; Ah Soune, P; Gilletta, C; Plastaras, L; Simon, M; Dray, X; Caillo, L; Del Tedeco, E; Abitbol, V; Zallot, C Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S408 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P455 Spacing of infliximab infusions over 8 weeks in patients with inflammatory bowel diseases in clinical remission: Final results of a retrospective multicentre French national cohort. (16th January 2018) Authors: Dufour, G; Pariente, B; Amiot, A; Viennot, S; Zerbib, F; Caillo, L; Nancey, S; Pouderoux, P; Poullenot, F; Altwegg, R; Peyrin-Biroulet, L; Nachury, M; Blanc, P; Pineton de Chambrun, G Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S334 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P604 Infection Risk in Elderly Patients with Inflammatory Bowel Disease under anti-TNF, ustekinumab or vedolizumab biologic therapies: A Prospective Multicenter observational One-Year follow-up comparative study. (21st January 2022) Authors: Bozon, A; Serrero, M; Caillo, L; Gilletta, C; Benezech, A; Nancey, S; Combes, R; Danan, G; Akouete, S; Pages, L; Bourgaux, J F; Boivineau, L; Meszaros, M; Altwegg, R Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i537 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P207 COVID-19: a prevalence rate two times lower than that of the general population in French patients with Inflammatory Bowel Disease treated with intravenous biologic agents. (21st January 2022) Authors: Lelong, M; Nancey, S; Bouguen, G; Allez, M; Serrero, M; Chupin, A; Caillo, L; Viennot, S; Blanc, P; Reimund, J M; Laharie, D; Olivier, R; Laurent, P B; Dib, N; De Maissin, A; Montuclard, C; Trang-Poisson, C; Gaillot, G; Bressollette-Bodin, C; Berthome, M Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i265 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P558 Should we introduce early a new biological agent in patients with Inflammatory Bowel Disease after anti-TNF discontinuation due to severe anti-TNF-induced skin lesions? A multicenter cohort study. (21st January 2022) Authors: Cottron, C; Treton, X; Altwegg, R; Reenaers, C; Amiot, A; Fumery, M; Vuitton, L; Peyrin-Biroulet, L; Bouguen, G; Dewit, O; Nancey, S; Caillo, L; Roblin, X; Beylot-Barry, M; Rivière, P; Laharie, D Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i502 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort Study. (26th February 2022) Authors: Cottron, C; Treton, X; Altwegg, R; Reenaers, C; Amiot, A; Fumery, M; Vuitton, L; Peyrin-Biroulet, L; Bouguen, G; Dewit, O; Nancey, S; Caillo, L; Roblin, X; Beylot-Barry, M; Rivière, P; Laharie, D Journal: Journal of Crohn's and colitis Issue: Volume 16:Number 8(2022) Page Start: 1202 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. DOP89 Impact of biologics on the risk of early postoperative complications in Crohn's disease: a French nationwide study. (30th January 2023) Authors: Fumery, M; Nancey, S; Nachury, M; Allez, M; Rouillon, C; Boureille, A; Altwegg, R; Serrero, M; Vuitton, L; Bouguen, G; Abitbol, V; Boualit, M; Biron, A; Panis, Y; Laharie, D; Amiot, A; Simon, M; Caillo, L; Hébuterne, X; Vidon, M Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i166 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P579 Real-world comparison of effectiveness between tofacitinib and ustekinumab in patients with ulcerative colitis exposed to at least one anti-TNF agent: results from the TORUS study. (30th January 2023) Authors: Buisson, A; Serrero, M; Altwegg, R; Guilmoteau, T; Bouguen, G; Nachury, M; Amiot, A; Vuitton, L; Treton, X; Caillo, L; Pereira, B; Fumery, M Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i707 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗